Wechselwirkungen · Eviplera
Eviplera 200 mg/25 mg/245 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 20
HOS-214424 · Präparat HOS-155326
Rilpivirine: AUC: ↔ Vardenafil2 Cmin: ↔ Tadalafil2 Cmax: ↔ Sildenafil/Tenofovir disoproxil Interaction not studied. N/A = not applicable 1 This interaction study has been performed with a dose higher than the recommended dose for rilpivirine hydrochloride assessing the maximal effect on the co-administered medicinal product. The dosing recommendation is applicable to the recommended dose of rilpivirine of 25 mg once daily. 2 These are medicinal products within class where similar interactions could be predicted. 3 This interaction study has been performed with a dose higher than the recommended dose for rilpivirine hydrochloride assessing the maximal effect on the co-administered medicinal product. 4 The predominant circulating metabolite of sofosbuvir. 5 Study conducted with additional voxilaprevir 100 mg to achieve voxilaprevir exposures expected in hepatitis C virus (HCV) infected patients. 6 Study conducted with emtricitabine/rilpivirine/tenofovir alafenamide fixed-dose combination tablet.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sofosbuvir (HOS-108928) tenofovir alafenamide (HOS-110476) hepatitis C virus (HOS-108813) voxilaprevir (HOS-108930) sildenafil (HOS-086162)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-06-19T11:57:00Z · SHA-256 3873fd554f54608c25be65a5e155834d2d4981603221b5f24abb68e92e1af40e · Passage 3d8af4c36539b31163652aabd90d80a7a470c72f82ae45503aa509416263358a · Zeichen 40582–41715 im Abschnitt